Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/93063
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Nonreceipt of antenatal magnesium sulphate for fetal neuroprotection at the Women's and Children's Hospital, Adelaide 2010-2013
Author: Siwicki, K.
Bain, E.
Bubner, T.
Ashwood, P.
Middleton, P.
Crowther, C.
Citation: Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015; 55(3):233-238
Publisher: Wiley
Issue Date: 2015
ISSN: 1479-828X
1479-828X
Statement of
Responsibility: 
Kasia Siwicki, Emily Bain, Tanya Bubner, Pat Ashwood, Philippa Middleton and Caroline A. Crowther
Abstract: BACKGROUND: Australian and New Zealand clinical practice guidelines, endorsed by the NHMRC in 2010, recommend administration of antenatal magnesium sulphate to women at risk of imminent preterm birth at less than 30 weeks' gestation to reduce the risk of their very preterm babies dying or having cerebral palsy. The purpose of the ongoing Working to Improve Survival and Health for babies born very preterm (WISH) implementation project is to monitor and improve the uptake of this neuroprotective therapy across Australia and New Zealand. AIMS: To quantify and explore reasons for nonreceipt of antenatal magnesium sulphate at the Women's and Children's Hospital, in Adelaide, South Australia. MATERIALS AND METHODS: Data from the case records of women who gave birth between 23(+0) and 29(+6)  weeks' gestation from 2010 to mid-2013 were reviewed to determine the proportion of eligible mothers not receiving antenatal magnesium sulphate and to explore reason(s) for nonreceipt over this time period. RESULTS: There was a reduction in the proportion of eligible mothers not receiving antenatal magnesium sulphate from 2010 (69.7%) to 2011 (26.9%), which was maintained in 2012 and 2013 (22.5%). In 2012-2013, nonreceipt was predominantly associated with immediately imminent (advanced labour, rapid progression of labour) or indicated emergent birth (actual or suspected maternal or fetal compromise). CONCLUSIONS: Use of antenatal magnesium sulphate at the Women's and Children's Hospital is now predominantly in-line with the binational guideline recommendations. Ongoing education and enhanced familiarity with procedures may facilitate timely administration in the context of some precipitous or immediately imminent births.
Keywords: cerebral palsy; clinical audit; magnesium sulphate; pregnancy; preterm birth
Rights: © 2015 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists
RMID: 0030030685
DOI: 10.1111/ajo.12334
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.